

06<sup>th</sup> May, 2022

The Dy. General Manager (Listing Dept.)  
BSE Limited,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

**Sub.: Intimation of the date of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

---

We would like to inform you that:

1. A meeting of the Board of Directors will be held on Wednesday, 25-May-22, *inter alia*, to consider and approve the Audited Financial Results of the Company for the year ended on 31-Mar-22.
2. In the above meeting, the Board would also consider the following:
  - i. Recommendation of final dividend, if any, on the equity shares of the Company, for the year 2021-22.
  - ii. Taking enabling resolutions for raising of funds by issue of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes.

If approved by the Board of Directors, the said item will be placed for Shareholders' approval in the ensuing Annual General Meeting.

Kindly take note of the above.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL  
VP (LEGAL) & COMPANY SECRETARY